224 related articles for article (PubMed ID: 20668531)
21. PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Ono H; Basson MD; Ito H
Mol Cancer Res; 2015 Aug; 13(8):1174-84. PubMed ID: 26013168
[TBL] [Abstract][Full Text] [Related]
22. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
[TBL] [Abstract][Full Text] [Related]
23. The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin.
Brauer PM; Zheng Y; Evans MD; Dominguez-Brauer C; Peehl DM; Tyner AL
PLoS One; 2011 Mar; 6(3):e14789. PubMed ID: 21479203
[TBL] [Abstract][Full Text] [Related]
24. Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells-evidence for a NF-kappaB-dependent survival mechanism.
Garrouste F; Remacle-Bonnet M; Fauriat C; Marvaldi J; Luis J; Pommier G
Cell Death Differ; 2002 Jul; 9(7):768-79. PubMed ID: 12058282
[TBL] [Abstract][Full Text] [Related]
25. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
26. Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor.
Zheng Y; Peng M; Wang Z; Asara JM; Tyner AL
Mol Cell Biol; 2010 Sep; 30(17):4280-92. PubMed ID: 20606012
[TBL] [Abstract][Full Text] [Related]
27. Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer.
Mathur PS; Gierut JJ; Guzman G; Xie H; Xicola RM; Llor X; Chastkofsky MI; Perekatt AO; Tyner AL
Mol Cancer Res; 2016 Jun; 14(6):563-73. PubMed ID: 26983689
[TBL] [Abstract][Full Text] [Related]
28. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
29. PTK6 promotes degradation of c-Cbl through PTK6-mediated phosphorylation.
Kang SA; Lee ST
Biochem Biophys Res Commun; 2013 Feb; 431(4):734-9. PubMed ID: 23352614
[TBL] [Abstract][Full Text] [Related]
30. PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.
Ito K; Park SH; Katsyv I; Zhang W; De Angelis C; Schiff R; Irie HY
NPJ Breast Cancer; 2017; 3():45. PubMed ID: 29167821
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
Aubele M; Walch AK; Ludyga N; Braselmann H; Atkinson MJ; Luber B; Auer G; Tapio S; Cooke T; Bartlett JM
Br J Cancer; 2008 Oct; 99(7):1089-95. PubMed ID: 18781181
[TBL] [Abstract][Full Text] [Related]
32. The interaction of protein-tyrosine phosphatase α (PTPα) and RACK1 protein enables insulin-like growth factor 1 (IGF-1)-stimulated Abl-dependent and -independent tyrosine phosphorylation of PTPα.
Khanna RS; Le HT; Wang J; Fung TC; Pallen CJ
J Biol Chem; 2015 Apr; 290(15):9886-95. PubMed ID: 25694432
[TBL] [Abstract][Full Text] [Related]
33. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma.
Ma S; Bao JYJ; Kwan PS; Chan YP; Tong CM; Fu L; Zhang N; Tong AHY; Qin YR; Tsao SW; Chan KW; Lok S; Guan XY
Gastroenterology; 2012 Sep; 143(3):675-686.e12. PubMed ID: 22705009
[TBL] [Abstract][Full Text] [Related]
34. Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cells.
Wu YC; Zhu M; Robertson DM
PLoS One; 2012; 7(8):e42483. PubMed ID: 22879999
[TBL] [Abstract][Full Text] [Related]
35. Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells.
Brauer PM; Zheng Y; Wang L; Tyner AL
Cell Cycle; 2010 Oct; 9(20):4190-9. PubMed ID: 20953141
[TBL] [Abstract][Full Text] [Related]
36. IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma.
Gao L; Wang X; Wang X; Zhang L; Qiang C; Chang S; Ren W; Li S; Yang Y; Tong D; Chen C; Li Z; Song T; Zhi K; Huang C
Oncotarget; 2014 May; 5(9):2562-74. PubMed ID: 24810113
[TBL] [Abstract][Full Text] [Related]
37. LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis.
Li H; Baldwin BR; Zahnow CA
Mol Cancer; 2011 Aug; 10():100. PubMed ID: 21854628
[TBL] [Abstract][Full Text] [Related]
38. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
Fujita M; Ieguchi K; Cedano-Prieto DM; Fong A; Wilkerson C; Chen JQ; Wu M; Lo SH; Cheung AT; Wilson MD; Cardiff RD; Borowsky AD; Takada YK; Takada Y
J Biol Chem; 2013 Jul; 288(27):19593-603. PubMed ID: 23696648
[TBL] [Abstract][Full Text] [Related]
39. Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth.
Blakesley VA; Koval AP; Stannard BS; Scrimgeour A; LeRoith D
J Biol Chem; 1998 Jul; 273(29):18411-22. PubMed ID: 9660809
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
Yu L; Saile K; Swartz CD; He H; Zheng X; Kissling GE; Di X; Lucas S; Robboy SJ; Dixon D
Mol Med; 2008; 14(5-6):264-75. PubMed ID: 18231572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
